|June 24, 2014|
|Verastem’s Published Scientific Data on Targeting Mesothelioma Cancer Stem Cells Receives Coverage in AACR’s Cancer Discovery|
- The Registration-Directed COMMAND Study of VS-6063 for Patients
with Malignant Pleural Mesothelioma to be Highlighted at the Company’s
Upcoming R&D Day on
Two of Verastem’s lead drug candidates, VS-6063 and VS-4718, target cancer stem cells through potent inhibition of FAK. Cancer stem cells are an underlying cause of tumor resistance to chemotherapy, recurrence and ultimate disease progression. VS-6063 is currently being studied in the registration-directed COMMAND trial in mesothelioma (www.COMMANDmeso.com) and VS-4718 is currently in a Phase 1 clinical trial in patients with advanced solid tumors.
The Cancer Discovery commentary can be accessed at http://bit.ly/1qsDCMo
The Science Translational Medicine paper on VS-4718 that is the subject of the commentary can be accessed at http://bit.ly/1imOZp8
The Company will provide an overview of these programs at its upcoming
Research and Development Day being held on
Special guest speakers to include:
Annual Research and Development Day Details and Webcast Info
A replay of the webcast will be archived for 90 days following the
About Malignant Pleural Mesothelioma
Malignant pleural mesothelioma is an aggressive form of cancer that
occurs in the mesothelium, the thin layer of tissue that covers the
lungs. Mesothelioma is associated with exposure to asbestos in most
cases. According to the
VS-6063 (defactinib) is an orally available compound designed to target
cancer stem cells through the potent inhibition of focal adhesion kinase
(FAK). Cancer stem cells are an underlying cause of tumor resistance to
chemotherapy, recurrence and ultimate disease progression. Research by
COMMAND is a registration-directed, double-blind, placebo-controlled trial of VS-6063 with Progression Free Survival (PFS) and Overall Survival (OS) as the primary endpoints. VS-6063 targets cancer stem cells. Cancer stem cells are an underlying cause of tumor progression and recurrence. The design of COMMAND allows the opportunity to enrich for patients with tumors low in the biomarker, merlin. Preclinical and early clinical research has demonstrated that low merlin levels may be predictive of increased effectiveness of FAK inhibitors such as VS-6063. The COMMAND study stratifies patients to evaluate the effect of VS-6063 in both the overall patient population and the subgroup of patients whose tumors are low in merlin.
COMMAND is expected to enroll approximately 350-400 patients at clinical
sites in 12 countries, including the US,
VS-4718 is an orally available compound designed to target cancer stem cells through the potent inhibition of focal adhesion kinase (FAK). VS-4718 is currently being studied in a Phase 1 dose escalation study in patients with advanced cancers.
Any statements in this press release about future expectations, plans and prospects for the Company constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.
|You may automatically receive Verastem Oncology™ financial information by e-mail. To choose your options for e-mail notification, please enter your e-mail address below and click Submit. On the next page you will be able to choose from the following options:|
To change your e-mail options at any time, re-enter your e-mail address and click Submit, then adjust your form entries.